Policy Changes ImpactThe announced policy changes by the new US administration have led to uncertainty and delays in decision-making by Pharma and Biotech customers.
Policy UncertaintyPolicy uncertainty is slowing decision-making in the R&DS segment, with elongated decision cycles and impacted study starts.
R&DS Segment ChallengesDespite satisfactory RFP flows, R&DS bookings still lag below targets, contributing to depressed revenue growth in the segment.